Thomas Powles, MD, PhD, on Urothelial Carcinoma: Results From the RANGE Trial on Ramucirumab and Docetaxel
2019 Genitourinary Cancers SymposiumThomas Powles, MD, PhD, of Queen Mary University of London, discusses phase III study findings on ramucirumab plus docetaxel vs placebo plus docetaxel in patients with advanced platinum-refractory urothelial carcinoma (Abstract 353).
Related Videos
Sumanta K. Pal, MD, on Clinical Cancer Advances: The 14th Annual Report
Sumanta K. Pal, MD, of City of Hope, who served as a Co-Executive Editor of the 2019 publication Clinical Cancer Advances, discusses progress made during the past ye...
Nicholas J. van As, MD, on Prostate Cancer: Results From the PACE-B Trial Comparing Radiotherapy Techniques
Nicholas J. van As, MD, of The Royal Marsden NHS Foundation Trust, discusses an analysis of acute toxicity in the PACE-B study, which compared stereotactic body radiotherapy ...
Jason A. Efstathiou, MD, DPhil, on Bladder Cancer: What Is the Best Treatment Option?
Karim Fizazi, MD, PhD, on Prostate Cancer: Results From the ARAMIS Trial on Darolutamide
Craig R. Nichols, MD, on Testicular Cancer Cases: Should They Be Discussed With High-Volume Centers?
Craig R. Nichols, MD, of the Testicular Cancer Commons and the SWOG Group Chair's Office, discusses the superior outcomes obtained at high-volume centers, the impracticality ...
